Your browser doesn't support javascript.
loading
Immune perturbations in HIV-1-infected individuals who make broadly neutralizing antibodies.
Moody, M Anthony; Pedroza-Pacheco, Isabela; Vandergrift, Nathan A; Chui, Cecilia; Lloyd, Krissey E; Parks, Robert; Soderberg, Kelly A; Ogbe, Ane T; Cohen, Myron S; Liao, Hua-Xin; Gao, Feng; McMichael, Andrew J; Montefiori, David C; Verkoczy, Laurent; Kelsoe, Garnett; Huang, Jinghe; Shea, Patrick R; Connors, Mark; Borrow, Persephone; Haynes, Barton F.
Afiliação
  • Moody MA; Duke University Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA. hayne002@mc.duke.edu moody007@mc.duke.edu persephone.borrow@ndm.ox.ac.uk.
  • Pedroza-Pacheco I; Department of Immunology, Duke University School of Medicine, Durham, NC 27710, USA.
  • Vandergrift NA; Department of Pediatrics, Duke University School of Medicine, Durham, NC 27710, USA.
  • Chui C; Nuffield Department of Clinical Medicine, University of Oxford, Oxford OX3 7FZ, UK.
  • Lloyd KE; Duke University Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
  • Parks R; Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA.
  • Soderberg KA; Nuffield Department of Clinical Medicine, University of Oxford, Oxford OX3 7FZ, UK.
  • Ogbe AT; Duke University Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
  • Cohen MS; Duke University Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
  • Liao HX; Duke University Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
  • Gao F; Nuffield Department of Clinical Medicine, University of Oxford, Oxford OX3 7FZ, UK.
  • McMichael AJ; University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
  • Montefiori DC; Duke University Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
  • Verkoczy L; Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA.
  • Kelsoe G; Duke University Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
  • Huang J; Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA.
  • Shea PR; Nuffield Department of Clinical Medicine, University of Oxford, Oxford OX3 7FZ, UK.
  • Connors M; Department of Surgery, Duke University School of Medicine, Durham, NC 27710, USA.
  • Borrow P; Duke University Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
  • Haynes BF; Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA.
Sci Immunol ; 1(1): aag0851, 2016 Jul 29.
Article em En | MEDLINE | ID: mdl-28783677
ABSTRACT
Induction of broadly neutralizing antibodies (bnAbs) is a goal of HIV-1 vaccine development. bnAbs occur in some HIV-1-infected individuals and frequently have characteristics of autoantibodies. We have studied cohorts of HIV-1-infected individuals who made bnAbs and compared them with those who did not do so, and determined immune traits associated with the ability to produce bnAbs. HIV-1-infected individuals with bnAbs had a higher frequency of blood autoantibodies, a lower frequency of regulatory CD4+ T cells, a higher frequency of circulating memory T follicular helper CD4+ cells, and a higher T regulatory cell level of programmed cell death-1 expression compared with HIV-1-infected individuals without bnAbs. Thus, induction of HIV-1 bnAbs may require vaccination regimens that transiently mimic immunologic perturbations in HIV-1-infected individuals.

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2016 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2016 Tipo de documento: Article